TVGN Key Statistics, Chart & Performance
The current stock price of TVGN is 0.3807 USD. In the past month the price decreased by -20.85%. In the past year, price decreased by -63.04%.
TVGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About TVGN
Company Profile
Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
Company Info
TEVOGEN BIO HOLDINGS INC
15 Independence Boulevard, Suite #210
WARREN NEW JERSEY US
Employees: 18
Phone: 16468078832
TEVOGEN BIO HOLDINGS INC / TVGN FAQ
What does TVGN do?
Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
What is the current price of TVGN stock?
The current stock price of TVGN is 0.3807 USD. The price decreased by -3.84% in the last trading session.
Does TEVOGEN BIO HOLDINGS INC pay dividends?
TVGN does not pay a dividend.
How is the ChartMill rating for TEVOGEN BIO HOLDINGS INC?
TVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does TEVOGEN BIO HOLDINGS INC belong to?
TEVOGEN BIO HOLDINGS INC (TVGN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for TEVOGEN BIO HOLDINGS INC?
TEVOGEN BIO HOLDINGS INC (TVGN) will report earnings on 2026-03-25.
TVGN Technical Analysis
TVGN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TVGN. Both the profitability and financial health of TVGN have multiple concerns.
TVGN Financial Highlights
Over the last trailing twelve months TVGN reported a non-GAAP Earnings per Share(EPS) of 0.38. The EPS increased by 375% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 337.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVGN Forecast & Estimates
7 analysts have analysed TVGN and the average price target is 5.1 USD. This implies a price increase of 1239.64% is expected in the next year compared to the current price of 0.3807.